Nerenstone S R, Archer J I, Cheson B D
Emmes Corporation, Rockville, Maryland.
Oncology (Williston Park). 1987 Oct;1(8):31-40, 44.
Standard therapy for chronic lymphocytic leukemia has been an alkylating agent plus a corticosteroid, a palliative approach. But now, because of sophisticated cytogenetic and biologic evaluation of CLL patients leading to more accurate staging, plus interest in two new chemotherapy agents, 2'-deoxycoformycin and fludarabine monophosphate, different approaches to the therapy of CLL are being studied. These include combination chemotherapy programs, incorporating the new drugs with standard therapy, combining them with each other, and investigating novel biological agents. While no treatment has clearly altered the outcome of patients with CLL, clinical trials of patients without prior therapy, using new standardized criteria for response, are needed.
慢性淋巴细胞白血病的标准治疗方法一直是使用烷化剂加皮质类固醇，这是一种姑息治疗方法。但现在，由于对慢性淋巴细胞白血病患者进行了复杂的细胞遗传学和生物学评估，从而实现了更准确的分期，再加上对两种新型化疗药物——2'-脱氧助间型霉素和单磷酸氟达拉滨的关注，人们正在研究慢性淋巴细胞白血病的不同治疗方法。这些方法包括联合化疗方案，即将新药与标准疗法相结合、将新药彼此联合，以及研究新型生物制剂。虽然尚无治疗方法能明显改变慢性淋巴细胞白血病患者的预后，但仍需要对未接受过治疗的患者进行临床试验，并采用新的标准化疗效标准。
